Alternatives Watch的动态

New Post: SEC Form 10-Q filed by Sana Biotechnology Inc. – Quantisnow - Arch Venture Fund X, L.P. has acquired $9,999,996 in funding, focusing on Partner, Capital Solutions, and Value Realization. The fund collaborates with Limited Partners, alongside strategic and financial partners, to enhance its investment strategies and outcomes. This initiative aims to drive growth and innovation within its portfolio companies, leveraging a network of resources and expertise to maximize value for all stakeholders involved. The investment reflects Arch Venture Fund's commitment to fostering successful partnerships and achieving significant returns in the competitive venture capital landscape. Read the full article here https://lnkd.in/dHchYGW9 #Venturecapital #VC #investment #LP #Limited Partner

We are excited to announce that Deverra Therapeutics is raising capital on StartEngine. Due to our recent successes we are looking to continue our growth and are expanding our vision through an equity capital fundraising round. This is a really exciting moment for us as we reflect on how far we’ve come to get to this point and we are looking to bring on new investors. The best part is through StartEngine’s platform, we are able to host an equity crowdfunding campaign and open our fundraising round to all! ? What exactly is equity crowdfunding? Regulation Crowdfunding gives eligible companies of all types an opportunity to raise capital from the public. Investors hold partial ownership in the company and have the opportunity to benefit if the company does well. ? In the past, a startup could only offer and sell its securities to accredited investors and then only if it complied with complex federal and state registration requirements. Under the JOBS Act the general public can now invest in capital raising by start-up companies. For as little as $500, you can become an investor in Deverra and own a part of a company seeking remission for all. #AML #celltherapy #allogeneic #cordblood #seekingremissionforall #equitycrowdfunding #startengine #investingforall

Two mega-funds lately raised $3.630b and want to enable the next stage of biotech development. And these are ARCH Venture Partners and Frazier Life Sciences. Arch closed a fund with $3 billion in cash ready to be deployed in early to medium stage companies that their future holds strong drug blockbuster promise. They claimed they have the patience to wait even for decades down the line for the return to come for those ventures that worth the risk. Some of the companies already benefiting from Arch's fund are: - Arsenal Biosciences, Inc. - Mirador Therapeutics - Xaira Therapeutics - Metsera I assume their due diligence team is great enough to discover the "unseen" best to invest! And Frazier Life Sciences (FLS) has sourced a further $630 million for its fund. The focus will be on small and mid-cap biotechs. Around $1.7 billion have been raised since the fund was set up three years ago. While the fund is aiming to fund "turbulent" cash-starving small to medium size biotechs that have good science to justify the investment capital, FLS wants to jump in and fund - if after due diligence makes sense - later stage companies that need the money to propel their clinical stages. Together with J.P Morgan's Life Science fund (+$500m), now FLS and Arch are showing us some signs of re-emerging confidence into deployment of investment capital within the biotech industry.

Learn more about equity crowdinvesting and how the general public can now invest in capital raising by startup companies. Become a part owner in Deverra. We can't wait to welcome you! ?? #StartEngine #investtoday #BeatCancer #Remissionforall

LPs around the world seek some sort of exposure to the #biotech investment category and the market has spoken as to the Forbion platform, with the #Netherlands-based European #lifesciences fund manager raising over EUR 2 billion, exceeding targets for its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, by bringing in 1.2 billion euros ($1.3 billion) and 890 million euros ($980 million), respectively. This fundraise significantly overshoots the 1.35 billion euros ($1.5 billion) brought in by Forbion’s?previous funds—Forbion Ventures Fund VI and Forbion Growth Opportunities Fund II—in April 2023 - yes, just last year! Key recent, outstanding investment exits include Numab Therapeutics AG subsidiary Yellow Jersey Therapeutics, which was?acquired by Johnson & Johnson?for $1.25 billion in May, and radiopharma biotech Mariana Oncology, which was?bought by Novartis?for $1 billion in the same month! We had the opportunity to meet the Forbion leadership team earlier this year in London at the Institutional Limited Partners Association (ILPA) summit and they are indeed quite a remarkable team poised to identifying and backing great teams in the sector. Congratulations to all and looking forward to building the relationship! #alternativeassets #fundraising #fundmanagers #privatemarkets #europe #germany #crossborder #venturecapital #growthcapital #limitedpartners

Crowdfunding is breaking new ground in the biotech sector, offering alternative financial pathways for startups navigating high costs and regulatory hurdles. In an insightful read from Bit 2 Geek, Eric Reynolds discusses how platforms like WiSEED and Capital Cell are providing early-stage opportunities for biotech ventures. With success stories like ANTABIO and eyeBrain Medical, Inc., this piece delves into the potential and risks of crowdfunding in biotech innovation. https://lnkd.in/grNs_f6v #lifesciences

JP Morgan has recently closed its inaugural biotechnology venture capital fund. An exciting time for the industry with such a large fund being made available to support innovative companies across the industry. Moreso than the investment, businesses can gain the support and expertise to drive them towards successful outcomes and revolutionise the next generation of biotechnology companies. #VentureCapital #Investment #LifeSciences #Biotechnology

The first VC Fundraising Workshop organized by KHAN Technology Transfer Fund I and wings4innovation GmbH took place in Vienna this week. The aim of the workshop was for our portfolio companies CasInvent Pharma, Cutanos GmbH, KinSea Lead Discovery AS, and RIANA Therapeutics to share their experiences in raising venture capital and to learn from each other's best practices. The discussions were very constructive and I think everyone took away something for themselves and their company for the current financing rounds and perhaps already for the upcoming investor meetings at the BIO Spring conference. Good luck to all participants! Don't forget: Have your investment case clear, be selective in choosing the right investors and do your homework before you approach an investor!??? #venturecapital #seedfunding #seedcapital #fundraising

Noubar Afeyan announced that Flagship Pioneering raised $3.6B in a new funding round. $2.6B will go to Flagship Pioneering Fund VIII, and $1B will be going to what it described as side funds and sector-specific strategic partnerships. One thing is for sure, big things for the #biotech and #biopharma companies that they choose to support. https://lnkd.in/e8yiTjyG #vc #fundraising #venturecapital #Boston #biotechnology #investments #startups #leanstartups

Nice article covering our new fund in Investors in Healthcare Brandon Capital